Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
| Autor: | Ib Tønder Hansen, Kristian Stengaard-Pedersen, Julia S. Johansen, Peter Junker, Hanne Merete Lindegaard, Mikkel Østergaard, Torkell Ellingsen, Anette Jørgensen, Merete Lund Hetland, Hans Christian Horn, Sophine B. Krintel, Johnny Lillelund Raun, Mette Yde Dam, Christian Gytz Ammitzbøll, Palle Ahlquist, Annette Schlemmer, Jan Pødenphant, Opera study-group, Asta Linauskas, Kim Hørslev-Petersen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Triamcinolone acetonide Immunology Placebo-controlled study Antibodies Monoclonal Humanized Triamcinolone Severity of Illness Index Drug Administration Schedule General Biochemistry Genetics and Molecular Biology Injections Intra-Articular Arthritis Rheumatoid Antirheumatic Agents/administration & dosage Double-Blind Method Rheumatology Quality of life Internal medicine medicine Adalimumab Humans Immunology and Allergy Methotrexate/administration & dosage Aged business.industry Remission Induction Middle Aged medicine.disease Connective tissue disease Surgery Clinical trial Methotrexate Treatment Outcome Arthritis Rheumatoid/drug therapy Antirheumatic Agents Rheumatoid arthritis Quality of Life Triamcinolone/administration & dosage Drug Therapy Combination Female business Antibodies Monoclonal Humanized/administration & dosage medicine.drug |
| Zdroj: | Hørslev-Petersen, K, Hetland, M L, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Horn, H C, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Johansen, J S, Ostergaard, M, Stengaard-Pedersen, K & OPERA study-group 2014, ' Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study : An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial ', Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 654-661 . https://doi.org/10.1136/annrheumdis-2012-202735 Hørslev-Petersen, K, Hetland, M L, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Tønder Hansen, I, Horn, H C, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Johansen, J S, Østergaard, M, Stengaard-Pedersen, K & OPERA Study Group 2013, ' Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study : an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/annrheumdis-2012-202735 OPERA Study Group 2014, ' Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life : The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial ', Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 654-661 . https://doi.org/10.1136/annrheumdis-2012-202735 |
| ISSN: | 1468-2060 0003-4967 0066-0647 |
| DOI: | 10.1136/annrheumdis-2012-202735 |
| Popis: | OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRPMETHODS: In 14 Danish hospital-based clinics, 180 disease-modifying anti-rheumatic drugs (DMARD)-naïve ERA patients (RESULTS: Baseline characteristics were similar between groups. In the adalimumab group/placebo group the 12-month cumulative triamcinolone doses were 5.4/7.0 ml (p=0.08). Triple therapy was applied in 18/27 patients (p=0.17). At 12 months, DAS28CRPCONCLUSIONS: Adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment did not increase the proportion of patients who reached the DAS28CRP |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|